|View printer-friendly version|
|Incyte Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies|
Both INCB24360 and MPDL3280A are part of a new class of cancer treatments known as immunotherapies that are designed to enhance the body’s own defenses in fighting cancer; both agents target distinct regulatory components of the immune system.
“This collaboration with Genentech is a further illustration of our
desire to investigate the therapeutic value of our IDO1 inhibitor in
multiple tumor types as rapidly as possible,” stated Hervé Hoppenot,
President and Chief Executive Officer of
Under the terms of the collaboration,
INCB24360 is a member of a new class of cancer treatments known as immunotherapies. It is an orally bioavailable small molecule inhibitor of IDO1 that has nanomolar potency in both biochemical and cellular assays, potent activity in enhancing T lymphocyte, dendritic cell and natural killer cell responses in vitro, with a high degree of selectivity.
There is a growing body of evidence to suggest that IDO1 inhibitor-based
combination immunotherapy may improve clinical response. INCB24360 has
been shown to be active in mouse models of cancer as a single agent and
in combination with cytotoxic and immunotherapy agents, and its ability
to reduce tumor growth is dependent on a functional immune system –
consistent with its proposed mechanism of action. Preliminary clinical
data from an ongoing Phase I/II trial evaluating INCB24360 in
combination with the approved immunotherapy checkpoint inhibitor Yervoy®
(ipilimumab) in metastatic melanoma, recently presented at the 50th
Annual Meeting of the
In addition to the Phase I/II study in metastatic melanoma in
combination with ipilimumab (www.clinicaltrials.gov
Identifier: NCT01604889), described in the
MPDL3280A (also known as anti-PDL1) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1 (Programmed Death-Ligand 1). MPDL3280A is designed to make cancer cells more vulnerable to the body’s own immune system by interfering with PD-L1. PD-L1 is expressed on tumor cells and tumor-infiltrating immune cells, preventing them from binding to two receptors, PD-1 and B7.1, on the surface of T cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set
forth in this press release, including without limitation statements
with respect to the potential efficacy, safety and therapeutic value of,
and Incyte’s plans for, INCB24360, the plans and expectations regarding
the combination study, and the potential value of research
collaborations, contain predictions and estimates and are
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on Incyte’s current
expectations and subject to risks and uncertainties that may cause
actual results to differ materially, including unanticipated
developments in and risks related to the efficacy or safety of
INCB24360, the results of further research and development, the high
degree of risk and uncertainty associated with drug development,
clinical trials and regulatory approval processes, other market or
economic factors, competitive and technological advances, and other
risks detailed from time to time in